In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and ...
Elevara Medicines secured $70 million in Series A funding to advance ELV001's Phase II trial for rheumatoid arthritis and explore other chronic inflammatory conditions. Pharma investments surge as ...
Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...
Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices? Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback